Published in Virology on January 30, 1984
Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J Virol (1988) 3.84
Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies. J Virol (1986) 3.31
Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence. J Virol (1986) 2.35
Critical epitopes in transmissible gastroenteritis virus neutralization. J Virol (1986) 2.05
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol (2004) 1.80
Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. J Virol (1992) 1.75
Effective clearance of mouse hepatitis virus from the central nervous system requires both CD4+ and CD8+ T cells. J Virol (1990) 1.70
Demyelination determinants map to the spike glycoprotein gene of coronavirus mouse hepatitis virus. J Virol (2000) 1.55
Mouse hepatitis virus is cleared from the central nervous systems of mice lacking perforin-mediated cytolysis. J Virol (1997) 1.54
Characterization of a variant virus selected in rat brains after infection by coronavirus mouse hepatitis virus JHM. J Virol (1985) 1.48
Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice. J Virol (1986) 1.47
CD8+ T-cell epitopes within the surface glycoprotein of a neurotropic coronavirus and correlation with pathogenicity. J Virol (1995) 1.43
Antibody inhibits defined stages in the pathogenesis of reovirus serotype 3 infection of the central nervous system. J Exp Med (1989) 1.41
Antibody-induced restriction of viral gene expression in measles encephalitis in rats. J Virol (1990) 1.36
Mouse hepatitis virus-specific cytotoxic T lymphocytes protect from lethal infection without eliminating virus from the central nervous system. J Virol (1995) 1.34
Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J Virol (1985) 1.23
Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus. J Virol (1997) 1.22
Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein. J Virol (2003) 1.16
Amino acid sequence of a conserved neutralizing epitope of murine coronaviruses. J Virol (1989) 1.15
Localization of a neutralization site of Theiler's murine encephalomyelitis viruses. J Virol (1985) 1.13
Both spike and background genes contribute to murine coronavirus neurovirulence. J Virol (2006) 1.11
Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci U S A (1999) 1.11
Characterization of mouse hepatitis virus-specific cytotoxic T cells derived from the central nervous system of mice infected with the JHM strain. J Virol (1993) 1.09
Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase. J Virol (1997) 1.08
Control of central nervous system viral persistence by neutralizing antibody. J Virol (2003) 1.05
Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection. J Virol (1990) 1.05
Viral induction of central nervous system innate immune responses. J Virol (2005) 1.02
The spike glycoprotein of murine coronavirus MHV-JHM mediates receptor-independent infection and spread in the central nervous systems of Ceacam1a-/- Mice. J Virol (2007) 1.01
Pathogenesis of murine coronavirus in the central nervous system. J Neuroimmune Pharmacol (2010) 0.99
Expression of viral antigens in the central nervous system of visna-infected sheep: an immunohistochemical study on experimental visna induced by virus strains of increased neurovirulence. Acta Neuropathol (1989) 0.98
Antibody-dependent transcriptional regulation of measles virus in persistently infected neural cells. J Virol (1992) 0.97
Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis. J Virol (1986) 0.96
Catabolism of homologous murine monoclonal hybridoma IgG antibodies in mice. Immunology (1987) 0.94
Murine coronavirus receptors are differentially expressed in the central nervous system and play virus strain-dependent roles in neuronal spread. J Virol (2010) 0.93
Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts. J Virol (2000) 0.92
The pathogenic role of virus-specific antibody-secreting cells in the central nervous system of rats with different susceptibility to coronavirus-induced demyelinating encephalitis. Immunology (1991) 0.92
Spread of a neurotropic coronavirus to spinal cord white matter via neurons and astrocytes. J Virol (1995) 0.90
The pathogenesis of murine coronavirus infection of the central nervous system. Crit Rev Immunol (2010) 0.90
Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus. Am J Pathol (2005) 0.90
Hemagglutinin-esterase-specific monoclonal antibodies alter the neuropathogenicity of mouse hepatitis virus. J Virol (1992) 0.90
Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. J Virol (1996) 0.89
Localization of a passively transferred human recombinant monoclonal antibody to herpes simplex virus glycoprotein D to infected nerve fibers and sensory neurons in vivo. J Virol (1999) 0.88
Vaccination against lethal coronavirus-induced encephalitis with a synthetic decapeptide homologous to a domain in the predicted peplomer stalk. J Virol (1988) 0.88
Effect of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain. J Exp Med (1990) 0.87
Contributions of the viral genetic background and a single amino acid substitution in an immunodominant CD8+ T-cell epitope to murine coronavirus neurovirulence. J Virol (2005) 0.85
Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides. Virology (2000) 0.85
In vivo and in vitro models of demyelinating disease: efficiency of virus spread and formation of infectious centers among glial cells is genetically determined by the murine host. J Virol (1988) 0.83
Priming of CD8+ T cells during central nervous system infection with a murine coronavirus is strain dependent. J Virol (2008) 0.83
Epitope-specific antibody responses to virulent and avirulent feline infectious peritonitis virus isolates. J Clin Microbiol (1987) 0.82
Functional differences in the peplomer glycoproteins of feline coronavirus isolates. J Virol (1987) 0.82
Regulation of proinflammatory cytokine expression in primary mouse astrocytes by coronavirus infection. J Virol (2009) 0.80
The Biology of Persistent Infection: Inflammation and Demyelination following Murine Coronavirus Infection of the Central Nervous System. Curr Immunol Rev (2009) 0.80
The spike protein of murine coronavirus regulates viral genome transport from the cell surface to the endoplasmic reticulum during infection. J Virol (2009) 0.80
Mouse hepatitis virus infection of the CNS: a model for defense, disease, and repair. Front Biosci (2008) 0.78
The chemokine receptor CXCR2 and coronavirus-induced neurologic disease. Virology (2013) 0.77
Antibodies to varicella-zoster virus modulate antigen distribution but fail to induce viral persistence in vitro. J Virol (1992) 0.77
Specificity of the H-2 L(d)-restricted cytotoxic T-lymphocyte response to the mouse hepatitis virus nucleocapsid protein. J Virol (1996) 0.76
Effect of adoptive transfer of CD4, CD8 and B cells on recovery from MHV3-induced immunodeficiencies. Immunology (1996) 0.75
Common variable immunodeficiency presenting as herpes simplex virus encephalitis. J Allergy Clin Immunol (2010) 0.75
The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol (1980) 6.24
Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology (1981) 3.26
Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell--cell fusion. Virology (1982) 2.94
Coronavirus spike proteins in viral entry and pathogenesis. Virology (2001) 2.85
Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus. Virology (1987) 2.53
Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence. J Virol (1986) 2.35
Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein. J Virol (1991) 2.16
Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08
A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination. J Virol (2000) 2.04
Protein structure of lymphocytic choriomeningitis virus: evidence for a cell-associated precursor of the virion glycopeptides. Virology (1979) 2.00
Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol (1986) 1.95
Murine coronavirus infection: a paradigm for virus-induced demyelinating disease. Trends Microbiol (1997) 1.93
The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol (2000) 1.91
Site-specific antibodies define a cleavage site conserved among arenavirus GP-C glycoproteins. J Virol (1987) 1.87
Dynamic regulation of alpha- and beta-chemokine expression in the central nervous system during mouse hepatitis virus-induced demyelinating disease. J Immunol (1998) 1.83
The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol (2001) 1.80
Sequence analysis reveals extensive polymorphism and evidence of deletions within the E2 glycoprotein gene of several strains of murine hepatitis virus. Virology (1989) 1.79
The S RNA segment of lymphocytic choriomeningitis virus codes for the nucleoprotein and glycoproteins 1 and 2. J Virol (1985) 1.74
Restricted expression of viral glycoprotein in cells of persistently infected mice. Nature (1982) 1.73
Proteins of lymphocytic choriomeningitis virus: antigenic topography of the viral glycoproteins. Virology (1986) 1.71
Fine mapping of a peptide sequence containing an antigenic site conserved among arenaviruses. Virology (1988) 1.70
Acidic pH triggers LCMV membrane fusion activity and conformational change in the glycoprotein spike. Virology (1994) 1.70
Topographical mapping of epitopes on the glycoproteins of murine hepatitis virus-4 (strain JHM): correlation with biological activities. Virology (1984) 1.69
Protein-protein interactions in lymphocytic choriomeningitis virus. Virology (1991) 1.68
Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J Virol (1992) 1.66
Mouse hepatitis virus type 4 (JHM strains). induced fatal central nervous system disease. I. genetic control and murine neuron as the susceptible site of disease. J Exp Med (1981) 1.60
Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. J Virol (1985) 1.60
Western and dot immunoblotting analysis of viral antigens and antibodies: application to murine hepatitis virus. J Immunol Methods (1984) 1.58
Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus. Virology (1990) 1.58
Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology (1997) 1.57
Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein. J Virol (1990) 1.55
Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol (1996) 1.55
Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol (1989) 1.55
A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology (1997) 1.54
Survival of human carrier erythrocytes in vivo. Clin Sci (Lond) (1999) 1.53
Virus and immune responses: lymphocytic choriomeningitis virus as a prototype model of viral pathogenesis. Br Med Bull (1985) 1.52
Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition. J Exp Med (1985) 1.46
Virus persistence and recurring demyelination produced by a temperature-sensitive mutant of MHV-4. Nature (1982) 1.46
Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: a prospective study. J Hosp Infect (2002) 1.43
Protein structure of lymphocytic choriomeningitis virus: identification of the virus structural and cell associated polypeptides. Virology (1978) 1.43
Analysis of the genomic L RNA segment from lymphocytic choriomeningitis virus. Virology (1987) 1.43
Neutralizing epitopes of lymphocytic choriomeningitis virus are conformational and require both glycosylation and disulfide bonds for expression. Virology (1989) 1.41
The reticuloendothelium as the target in a virus infection. Pichinde virus pathogenesis in two strains of hamsters. Lab Invest (1977) 1.41
Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection. J Virol (1991) 1.40
Selective localization of wild type and mutant mouse hepatitis virus (JHM strain) antigens in CNS tissue by fluorescence, light and electron microscopy. J Neuroimmunol (1981) 1.39
The V5A13.1 envelope glycoprotein deletion mutant of mouse hepatitis virus type-4 is neuroattenuated by its reduced rate of spread in the central nervous system. Virology (1992) 1.39
Kinetics and pH dependence of acid-induced structural changes in the lymphocytic choriomeningitis virus glycoprotein complex. Virology (1995) 1.37
Ultrastructural localization of viral antigens in the CNS of mice persistently infected with lymphocytic choriomeningitis virus (LCMV). Am J Pathol (1983) 1.37
Systemic alpha-interferon therapy of multiple sclerosis. Neurology (1984) 1.35
Neuroinvasion by human respiratory coronaviruses. J Virol (2000) 1.33
Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology (1992) 1.32
Cell receptor-independent infection by a neurotropic murine coronavirus. Virology (1992) 1.31
Variation between strains of hamsters in the lethality of Pichinde virus infections. Infect Immun (1977) 1.28
Cytokine induction during T-cell-mediated clearance of mouse hepatitis virus from neurons in vivo. J Virol (1994) 1.25
Virus-induced immune complex disease: identification of specific viral antigens and antibodies deposited in complexes during chronic lymphocytic choriomeningitis virus infection. J Immunol (1978) 1.24
A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology (1984) 1.24
Entry of mouse hepatitis virus into cells by endosomal and nonendosomal pathways. Virology (1997) 1.24
Immuno-gold localization of prion filaments in scrapie-infected hamster brains. Lab Invest (1987) 1.22
Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus. J Virol (1997) 1.22
Recommendations of the Coronavirus Study Group for the nomenclature of the structural proteins, mRNAs, and genes of coronaviruses. Virology (1990) 1.21
Perturbation of differentiated functions during viral infection in vivo. I. Relationship of lymphocytic choriomeningitis virus and host strains to growth hormone deficiency. Virology (1985) 1.21
Physicochemical properties of Marburg virus: evidence for three distinct virus strains and their relationship to Ebola virus. J Gen Virol (1988) 1.19
Disease activity markers in multiple sclerosis. Another look at suppressor cells defined by monoclonal antibodies OKT4, OKT5, and OKT8. J Neuroimmunol (1984) 1.18
Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity (1993) 1.18
Serial passage of microglial SIV results in selection of homogeneous env quasispecies in the brain. Virology (1995) 1.18
Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans (2007) 1.17
Protein analysis of defective interfering lymphocytic choriomeningitis virus and persistently infected cells. Virology (1979) 1.15
In vitro generation of human cytotoxic lymphocytes by virus. Viral glycoproteins induce nonspecific cell-mediated cytotoxicity without release of interferon. J Exp Med (1981) 1.13
Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology (1999) 1.12
Host genetic control of mouse hepatitis virus type 4 (JHM strain) replication. I. Restriction of virus amplification and spread in macrophages from resistant mice. J Gen Virol (1984) 1.12
Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci U S A (1999) 1.11
Protection from lethal coronavirus infection by immunoglobulin fragments. J Immunol (1995) 1.10
Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology (1995) 1.10
Survival of human coronaviruses 229E and OC43 in suspension and after drying onsurfaces: a possible source ofhospital-acquired infections. J Hosp Infect (2000) 1.09
Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol (2003) 1.09
Monoclonal antibodies to lymphocytic choriomeningitis virus react with pathogenic arenaviruses. Nature (1980) 1.06
Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody. Brief report. Arch Virol (1987) 1.06
Sequence analysis of the membrane protein gene of human coronavirus OC43 and evidence for O-glycosylation. J Gen Virol (1992) 1.06
In vitro expression in eukaryotic cells of a prion protein gene cloned from scrapie-infected mouse brain. Proc Natl Acad Sci U S A (1988) 1.04
Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay. J Virol Methods (2004) 1.04
Antigenic variation among murine coronaviruses: evidence for polymorphism on the peplomer glycoprotein, E2. Virus Res (1985) 1.04
In vivo expression of major histocompatibility complex molecules on oligodendrocytes and neurons during viral infection. Am J Pathol (2001) 1.04
Acute and persistent infection of human neural cell lines by human coronavirus OC43. J Virol (1999) 1.02
Selected mutants of mouse hepatitis virus type 4 (JHM strain) induce different CNS diseases. Pathobiology of disease induced by wild type and mutants ts8 and ts15 in BALB/c and SJL/J mice. Am J Pathol (1982) 1.02
Host genetic regulation of acute MHV-4 viral encephalomyelitis and acute experimental autoimmune encephalomyelitis in (BALB/cKe x SJL/J) recombinant-inbred mice. J Neuroimmunol (1985) 1.02
Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells. J Virol (1997) 1.02